CJC-1295 + Ipamorelin Blend vs CJC-1295 (No DAC)
CJC-1295 + Ipamorelin Blend (Combination product: GHRH analog (CJC-1295) + GHRP/ghrelin-receptor agonist (ipamorelin)) and CJC-1295 (No DAC) (GHRH analog (short-acting modified GHRH(1-29), aka Mod GRF 1-29)) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | CJC-1295 + Ipamorelin Blend | CJC-1295 (No DAC) |
|---|---|---|
| Compound class | Combination product: GHRH analog (CJC-1295) + GHRP/ghrelin-receptor agonist (ipamorelin) | GHRH analog (short-acting modified GHRH(1-29), aka Mod GRF 1-29) |
| Research category | Growth & GH-Axis | Growth & GH-Axis |
| Length (amino acids) | Not documented | 29 amino acids |
| Molecular weight | Not documented | Approximately 3368 g/mol |
| Half-life | Not documented | Short, on the order of tens of minutes (reported approximately 30 minutes), longer than native GHRH but far shorter than the DAC version |
| Origin | This is not a single molecule but a formulated blend combining CJC-1295 (a GHRH analog) with ipamorelin (a selective ghrelin-receptor GH secretagogue). Blends are commonly prepared in research/compounding contexts to combine two complementary GH-stimulating mechanisms. | CJC-1295 without DAC (commonly called Mod GRF 1-29 or Modified GRF 1-29) is a modified GHRH(1-29) analog carrying stabilizing amino-acid substitutions but lacking the albumin-binding Drug Affinity Complex (DAC) of the full CJC-1295. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How CJC-1295 + Ipamorelin Blend works
The blend pairs two distinct mechanisms: CJC-1295 agonizes the GHRH receptor while ipamorelin agonizes the growth-hormone secretagogue (ghrelin) receptor. Because GHRH analogs and GHRPs act on separate pituitary pathways, their combined administration is studied for potentially synergistic, greater-than-additive GH release. Ipamorelin's selectivity is intended to add GH stimulation without notably raising cortisol or prolactin.
How CJC-1295 (No DAC) works
This peptide is a GHRH-receptor agonist that stimulates pulsatile GH release from the pituitary. Its four amino-acid substitutions on the GHRH(1-29) backbone (e.g. at positions 2, 8, 15, 27) resist DPP-4 degradation, giving it a modestly longer half-life than native sermorelin. Without the DAC group, it does not bind albumin, so it produces short, discrete GH pulses rather than sustained elevation.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
CJC-1295 + Ipamorelin Blend
CJC-1295 (No DAC)
What sets each apart
CJC-1295 + Ipamorelin Blend
Unlike single-agent GHRH analogs or GHRPs, this is a combination formulation designed to engage both the GHRH and ghrelin receptor pathways simultaneously.
CJC-1295 (No DAC)
The absence of the DAC albumin-binding group makes this a short-acting, pulse-generating GHRH analog, in direct contrast to the long-acting DAC version of CJC-1295.
Frequently asked questions
Does the blend use CJC-1295 with DAC or without DAC?
Blends vary by source. Many CJC-1295 + ipamorelin blends use the no-DAC (Mod GRF 1-29) form so that both components are short-acting and produce a clean pulsatile profile, but some use the DAC version for sustained GHRH tone. The specific form should be confirmed on the product's COA.
What is the CJC-1295 / Ipamorelin blend?
This is a combination research preparation containing both CJC-1295 (a GHRH analog) and ipamorelin (a selective GHRP / ghrelin-receptor agonist) in a single vial. It formalizes the most widely referenced GH-secretagogue research pairing into one product.
Why are CJC-1295 and ipamorelin combined?
The two act on different receptors: CJC-1295 on the GHRH receptor and ipamorelin on the ghrelin receptor (GHS-R1a). Stimulating both pathways simultaneously produces a synergistic GH pulse larger than either compound alone, which is the rationale for the blend in research settings.
What is CJC-1295 without DAC?
CJC-1295 without DAC (essentially Modified GRF 1-29) is a synthetic 29-amino-acid GHRH analog with four substitutions (at positions 2, 8, 15, and 27) that resist DPP-IV cleavage. Unlike the DAC version, it lacks the albumin-binding complex, so it is short-acting.
How does the no-DAC version differ from CJC-1295 with DAC?
Both share the same modified GHRH(1-29) core, but the no-DAC form has a half-life of only about 30 minutes and produces discrete GH pulses, whereas the DAC form binds albumin and lasts 6-8 days, giving sustained GHRH tone. The choice shapes whether research models pulsatile or sustained GH output.
Is CJC-1295 no-DAC the same as Modified GRF (1-29)?
Effectively yes. CJC-1295 without DAC and Modified GRF (1-29) refer to the same tetra-substituted GHRH(1-29) peptide; the naming differs by supplier but the sequence and short-acting profile are the same.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.